162 related articles for article (PubMed ID: 9438390)
1. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I.
d'Avis PY; Robertson SC; Meyer AN; Bardwell WM; Webster MK; Donoghue DJ
Cell Growth Differ; 1998 Jan; 9(1):71-8. PubMed ID: 9438390
[TBL] [Abstract][Full Text] [Related]
2. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Naski MC; Wang Q; Xu J; Ornitz DM
Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
[TBL] [Abstract][Full Text] [Related]
3. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
Adar R; Monsonego-Ornan E; David P; Yayon A
J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
[TBL] [Abstract][Full Text] [Related]
4. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.
Su WC; Kitagawa M; Xue N; Xie B; Garofalo S; Cho J; Deng C; Horton WA; Fu XY
Nature; 1997 Mar; 386(6622):288-92. PubMed ID: 9069288
[TBL] [Abstract][Full Text] [Related]
5. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data.
Tsai FJ; Tsai CH; Chang JG; Wu JY
Am J Med Genet; 1999 Sep; 86(3):300-1. PubMed ID: 10482885
[No Abstract] [Full Text] [Related]
7. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
[TBL] [Abstract][Full Text] [Related]
8. Japanese cases of type 1 thanatophoric dysplasia exclusively carry a C to T transition at nucleotide 742 of the fibroblast growth factor receptor 3 gene.
Pokharel RK; Alimsardjono H; Takeshima Y; Nakamura H; Naritomi K; Hirose S; Onishi S; Matsuo M
Biochem Biophys Res Commun; 1996 Oct; 227(1):236-9. PubMed ID: 8858131
[TBL] [Abstract][Full Text] [Related]
9. Thanatophoric dysplasia type I.
Chang TK; Wang Y; Liu AM; Tung JC
Acta Paediatr Taiwan; 2001; 42(1):39-41. PubMed ID: 11270184
[TBL] [Abstract][Full Text] [Related]
10. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
[TBL] [Abstract][Full Text] [Related]
11. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1.
Rousseau F; Saugier P; Le Merrer M; Munnich A; Delezoide AL; Maroteaux P; Bonaventure J; Narcy F; Sanak M
Nat Genet; 1995 May; 10(1):11-2. PubMed ID: 7647778
[No Abstract] [Full Text] [Related]
12. Parathyroid hormone receptor type 1/Indian hedgehog expression is preserved in the growth plate of human fetuses affected with fibroblast growth factor receptor type 3 activating mutations.
Cormier S; Delezoide AL; Benoist-Lasselin C; Legeai-Mallet L; Bonaventure J; Silve C
Am J Pathol; 2002 Oct; 161(4):1325-35. PubMed ID: 12368206
[TBL] [Abstract][Full Text] [Related]
13. Mutation associated with Crouzon syndrome causes ligand-independent dimerization and activation of FGF receptor-2.
Mangasarian K; Li Y; Mansukhani A; Basilico C
J Cell Physiol; 1997 Jul; 172(1):117-25. PubMed ID: 9207932
[TBL] [Abstract][Full Text] [Related]
14. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
[TBL] [Abstract][Full Text] [Related]
15. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
16. Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.
Del Piccolo N; Placone J; Hristova K
Biophys J; 2015 Jan; 108(2):272-8. PubMed ID: 25606676
[TBL] [Abstract][Full Text] [Related]
17. Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia Type I. Mutations in brief no. 199. Online.
Kitoh H; Brodie SG; Kupke KG; Lachman RS; Wilcox WR
Hum Mutat; 1998; 12(5):362-3. PubMed ID: 10671061
[TBL] [Abstract][Full Text] [Related]
18. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.
Bonaventure J; Horne WC; Baron R
FEBS J; 2007 Jun; 274(12):3078-93. PubMed ID: 17509076
[TBL] [Abstract][Full Text] [Related]
19. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
Lievens PM; Liboi E
J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
[TBL] [Abstract][Full Text] [Related]
20. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.
Tavormina PL; Shiang R; Thompson LM; Zhu YZ; Wilkin DJ; Lachman RS; Wilcox WR; Rimoin DL; Cohn DH; Wasmuth JJ
Nat Genet; 1995 Mar; 9(3):321-8. PubMed ID: 7773297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
